耐利福平肺结核——对全球结核病控制而言，一种虽不常见但日益严峻的挑战之综述
Rifampicin Mono-Resistant Tuberculosis-A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control.
作者信息
Malenfant Jason H, Brewer Timothy F
机构信息
Public Health & Preventive Medicine Program, UCLA David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.
出版信息
Open Forum Infect Dis. 2021 Jan 28;8(2):ofab018. doi: 10.1093/ofid/ofab018. eCollection 2021 Feb.
Tuberculosis (TB) remains the leading cause of death by an infectious pathogen worldwide, and drug-resistant TB is a critical and rising obstacle to global control efforts. Most scientific studies and global TB efforts have focused on multidrug-resistant TB (MDR-TB), meaning isolates resistant to both isoniazid (INH) and rifampicin (RIF). Newer diagnostic tests are resulting in an increasing awareness of RIF-resistant TB in addition to MDR disease. To date, RIF resistance has been assumed to be synonymous with MDR-TB, but this approach may expose TB patients with RIF mono-resistance disease to unnecessarily long and toxic treatment regimens. We review what is currently known about RIF mono-resistant TB, its history and epidemiology, mechanisms of RIF resistance, available diagnostic techniques, treatment outcomes reported globally, and future directions for combatting this disease.
结核病（TB）仍然是全球范围内由传染性病原体导致死亡的首要原因，而耐药结核病是全球结核病防控工作的一个关键且日益严重的障碍。大多数科学研究和全球结核病防治工作都集中在耐多药结核病（MDR-TB）上，即对异烟肼（INH）和利福平（RIF）均耐药的菌株。除了耐多药疾病外，新型诊断测试使人们对利福平耐药结核病的认识不断提高。迄今为止，利福平耐药一直被认为与耐多药结核病同义，但这种方法可能会使单纯利福平耐药结核病患者接受不必要的长期和毒性治疗方案。我们综述了目前关于单纯利福平耐药结核病的已知情况、其历史和流行病学、利福平耐药机制、可用的诊断技术、全球报告的治疗结果以及对抗这种疾病的未来方向。
Zotero 插件